Drug combo targets rare cancers in early trial
NCT ID NCT00336063
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests the combination of two drugs, vorinostat and azacitidine, in people with nasopharyngeal cancer or nasal NK-T cell lymphoma that has come back or spread. The main goal is to find the safest dose and see how the body responds. Only 18 participants are enrolled, so this is a small, preliminary study.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- vorinostat and azacitidine
- What this could lead to
- If it works, this could point toward a new drug combination for hard-to-treat nasopharyngeal cancer and NK-T cell lymphoma.
- What could go wrong
- This is a very early (Phase 1) trial with only 18 people, focused on finding a safe dose. It is not designed to prove the drugs shrink tumors or improve survival.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADULT NASAL TYPE EXTRANODAL NK/T-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Chinese University of Hong Kong-Prince of Wales Hospital
Shatin, Hong Kong
-
Johns Hopkins University/Sidney Kimmel Cancer Center
Baltimore, Maryland, 21287, United States
-
National Cancer Center Hospital
Tokyo, 104 0045, Japan
-
National Cancer Centre Singapore
Singapore, 168583, Singapore
-
National University Hospital Singapore
Singapore, 119074, Singapore
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New drug cocktail aims to tackle rare blood cancer
- Immunotherapy plus chemo shows promise for Tough-to-Treat nasopharyngeal cancer
- Immunotherapy boost may improve outcomes in returning throat cancer
- New surgery technique could improve survival in recurrent throat cancer
- New Two-Step transplant shows promise for blood cancer patients
- Proton beam takes aim at returning throat cancer